Questions that remain are whether in high-incidence countries there is better concordance between IGRAs and TST; can we define a lower interferon-γ cutoff value for patients who are immunocompromised or have HIV; is there a CD4 cutoff value below which these tests are no longer useful; and is IGRA positivity an accurate predictor of progression to active TB. This evidence concerns the gene CD4 and tuberculosis.